argenx NV ADR
$ 802.17
-4.06%
02 Jun - close price
- Market Cap 50,909,024,000 USD
- Current Price $ 802.17
- High / Low $ 823.68 / 799.68
- Stock P/E 36.22
- Book Value 4.73
- EPS 22.49
- Next Earning Report 2026-07-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.20 %
- 52 Week High 934.62
- 52 Week Low 510.06
About
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Analyst Target Price
$1031.96
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-05-08 | 2025-03-31 | 2024-10-31 | 2024-07-25 | 2024-05-09 | 2024-02-29 | 2023-10-31 | 2023-07-27 |
| Reported EPS | 4.7 | 6.7945 | 4.44 | 3.26 | 2.27 | 0.7125 | 1.28 | 0.41 | -0.97 | -1.68 | -1.18 | -1.53 |
| Estimated EPS | 4.19 | 5.95 | 3.54 | 2.61 | 2.05 | 1.6979 | 0.06 | -0.99 | -0.81 | -1.7 | -1.34 | -1.65 |
| Surprise | 0.51 | 0.8445 | 0.9 | 0.65 | 0.22 | -0.9854 | 1.22 | 1.4 | -0.16 | 0.02 | 0.16 | 0.12 |
| Surprise Percentage | 12.1718% | 14.1933% | 25.4237% | 24.9042% | 10.7317% | -58.0364% | 2033.3333% | 141.4141% | -19.7531% | 1.1765% | 11.9403% | 7.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-23 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 5.2 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARGX
2026-06-01 06:38:59
Argenx SE is gaining investor attention on Euronext Amsterdam following the presentation of new neuromuscular data for its drug Vyvgart at the AAN 2026 meeting. The biotech company continues to benefit from strong U.S. sales momentum, with 2025 revenue nearly doubling to over USD 4 billion, largely due to Vyvgart's uptake in generalized myasthenia gravis. Analysts maintain a predominantly positive outlook on the stock, treating Argenx increasingly as a mature commercial biotech.
2026-05-28 07:38:59
RBC Capital Markets noted that Argenx indicated confidence in a second-quarter rebound during its first-quarter earnings call. Despite mixed first-quarter results, the company's unchanged full-year guidance for efgartigimod sales suggests optimism for future performance. RBC maintains an Outperform rating on Argenx shares.
2026-05-28 06:09:58
argenx SE will host an R&D webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on June 23, 2026, at 2:00 PM ET. This webinar, part of a 'mini' series, will focus on myositis, a severe autoimmune rheumatic disease, discussing disease biology insights, the ALKIVIA clinical program, and the commercial potential of efgartigimod. The event aims to highlight the company's pipeline and research strategy in improving the lives of people suffering from severe autoimmune diseases.
2026-05-28 05:09:03
argenx, a global immunology company, will host an R&D webinar on June 23, 2026, focusing on autoimmune myositis. This webinar, part of a "mini" series, will discuss disease biology, the ALKIVIA clinical program, and the potential of efgartigimod. Leading clinicians and the argenx team will present insights into myositis, a disease marked by progressive muscle damage.
2026-05-27 23:40:15
Argenx SE is a commercial-stage biotechnology company with its flagship autoimmune drug, Vyvgart, driving revenue and a broad pipeline. The company's growth strategy centers on Vyvgart sales, pipeline development, and managing its cash position. Investors are closely monitoring Vyvgart's market penetration, additional indications, and the financial balance between product revenue and R&D spending, especially given its dual listing on Nasdaq and Euronext Brussels.
2026-05-27 18:40:15
This article focuses on Argenx SE and the growth trajectory of its flagship autoimmune drug, Vyvgart, following the latest quarterly update. It details the company's business model, key revenue drivers, and pipeline, highlighting the importance of Vyvgart's commercial performance and future indications for the biotech's valuation. The piece also notes the dual listing on Nasdaq and Euronext Brussels and the inherent risks in mid-cap biotech investments.
